It is believed that myasthenia gravis (MG) with antibodies to muscle-specific tyrosine kinase (MuSK) is the most severe form of the disease, especially in the first years of the disease. The aim of our study was to investigate quality of life (QoL) in a population of patients with MuSK MG compared to those with MG who have antibodies to acetylcholine receptor (AChR) in their sera. The study group consisted of 35 MuSK MG patients (28 females and 7 males), while the control group included 38 AChR MG patients matched for gender, age, and duration of the disease. SF-36 questionnaire was used to evaluate the health-related QoL. Following scales were also used: Hamilton’s scales for depression and anxiety, the Multidimensional Scale of Perceived Social Support, and the Acceptance of Illness Scale. Physical domain scores of QoL were similarly affected in both MuSK and AChR groups, while mental domain and total SF-36 scores were even better in MuSK MG patients. Social support was better in the MuSK group (77.3 ± 9.3 vs. 70.6 ± 14.1, p < 0.05). SF-36 total score correlated with depression (rho = 0.54, p < 0.01), anxiety (rho = 0.49, p < 0.01), and MSPSS (rho = − 0.35, p < 0.05), and depression was an independent predictor of worse QoL. Besides therapy of weakness, psychiatric treatment and different forms of psychosocial condition should be part of regular therapeutic protocols for MG. Adequate team work of health professionals and family can provide a healthy mental environment in which a MuSK MG patient would feel more comfortable in spite of the disease.
MuSK Myasthenia gravis Quality of life SF-36 questionnaire Depression Social support
This is a preview of subscription content, log in to check access.
This study was supported by the Ministry of Education, Science and Technological Development of Serbia (Grant #175083).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
Hoch W, McConville J et al (2001) Autoantibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7:365–368CrossRefPubMedGoogle Scholar
Tsonis AI, Zisimopoulou P, Lazaridis K et al (2015) MuSK autoantibodies in myasthenia gravis detected by cell-based assay—a multinational study. J Neuroimmunol 284:10–17CrossRefPubMedGoogle Scholar
Lavrnić D, Losen M, Vujić A, De Baets M, Lj Hajduković, Stojanović V, Trikić R, Đukić P, Apostolski S (2005) The features of myasthenia gravis with autoantibodies to MuSK. J Neural Neurosurg Psychiatry 76:1099–1102CrossRefGoogle Scholar
Basta I, Pekmezović T, Perić S, Kisić-Tapavčević D, Rakočević-Stojanović V, Stević Z, Lavrnić D (2012) Assesment of health-related quality of life in patients with myasthenia gravis in Belgrade (Serbia). Neurol Sci 33:1375–1381CrossRefPubMedGoogle Scholar
Parker L, Moran G, Roberts L, Calvert M, McCahon D (2014) The burden of common chronic disease on health-related quality of life in an elderly community-dwelling population in the UK. Fam Pract 31(5):557–563CrossRefPubMedGoogle Scholar
Lange B, Holst R, Thilsing T, Baelum J, Kjeldsen A (2013) Quality of life and associated factors in persons with chronic rhinosinusitis in the general population: a prospective questionnaire and clinical cross-sectional study. Clin Otolaryngol 38:474–480CrossRefPubMedGoogle Scholar
D’Alessandro R, Casmiro M, Benassi G, Rinaldi R, Gambeoni G (1995) Reliable disability scale for myasthenia gravis sensitive to clinical changes. Acta Neurol Scand 92:77–82CrossRefPubMedGoogle Scholar
Guy-Coichard C, Nguyen DT, Delorme T, Boureau F (2008) Pain in hereditary neuromuscular disorders and myasthenia gravis: a national survey of frequency characteristics, and impact. J Pain Symptom Manag 35:40–50CrossRefGoogle Scholar
Raggi A, Leonardi M, Mantegazza R, Casale S, Fioravanti G (2009) Social support and self-efficacy in patients with myasthenia gravis: a common pathway towards positive health outcomes. Neurol Sci 31:41–45CrossRefPubMedGoogle Scholar
Richards HS, Jenkinson E, Rumsey N, Harrad RA (2013) The psychosocial impact of ptosis as a symptom of myasthenia gravis: a qualitative study. Orbit 33(4):263–269CrossRefGoogle Scholar
Jeretzki A, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS et al (2000) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55:16–23CrossRefGoogle Scholar
Basta I, Pekmezovic T, Peric S, Nikolic A, Rakocevic-Stojanovic V, Stevic Z, Marjanovic I, Lavrnic D (2014) Extrathymic malignancies in a defined cohort of patients with myasthenia gravis. J Neurol Sci 346:80–84CrossRefPubMedGoogle Scholar
Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan W, Penn AS (1998) Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci 841:769–772CrossRefPubMedGoogle Scholar
Osserman KE, Genkins G (1971) Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. Mt Sinai J Med 38:497–536PubMedGoogle Scholar
Felton BJ, Revenson TA (1984) Coping with chronic illness: a study of illness controllability and influence of coping strategies on psychological adjustment. J Consult Clin Psychol 2:343–353CrossRefGoogle Scholar
Ware JE, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). Conceptual framework and item selection. Med Care 30:473–483CrossRefPubMedGoogle Scholar
Evoli A, Tonali PA, Padua L et al (2003) Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 126:2304–2311CrossRefPubMedGoogle Scholar
Vincent A, Bowen J, Newsom- Davis J et al (2003) Seronegative generalized myasthenia gravis: clinical features, antibodies, and their targets. Lancet Neural 2:99–106CrossRefGoogle Scholar
Sanders DB, El-Salem K, Massey JM et al (2003) Clinical aspects of MuSK antibody positive seronegative MG. Neurology 60:1978–1980CrossRefPubMedGoogle Scholar
Padua L, Evoli A, Aprile I, Caliandro P, Mazza S, Padua R et al (2001) Health-related quality of life in patients with myasthenia gravis and the relationship between patient-oriented assessment and conventional measurements. Neurol Sci 22:363–369CrossRefPubMedGoogle Scholar
Leonardi M, Raggi A, Antozzi C et al (2010) The relationship between health, disability, and quality of life in myasthenia gravis: results from an Italian study. J Neurol 257:98–102CrossRefPubMedGoogle Scholar
Pekmezovic T, Svetel M, Ivanovic N, Dragasevic N, Petrovic I, Kisic-Tepavcevic D et al (2009) Quality of life in patients with focal dystonia. Clin Neurol Neurosurg 111:161–164CrossRefPubMedGoogle Scholar
Svetel M, Pekmezovic T, Tomic A, Kresojevic N, Potrebic A, Jesic R et al (2011) Quality of life in patients with treated and clinically stable Wilson’s disease. Mov Disord 26:1503–1508CrossRefPubMedGoogle Scholar
Drulovic J, Pekmezovic T, Matejic B, Mesaros S, Manigoda M, Dujmovic I et al (2007) Quality of life in patients with multiple sclerosis in Serbia. Acta Neurol Scand 115:147–152CrossRefPubMedGoogle Scholar
Peric S, Rakocevic-Stojanovic V, Stevic Z, Basta I, Pavlovic S, Vujanac V et al (2010) Health-related quality of life in patients with myotonic dystropy type 1 and amyotrophic lateral sclerosis. Acta Neurol Belg 110:71–77PubMedGoogle Scholar
Bozovic I, Kacar A, Peric S, Nikolic A et al (2017) Quality of life predictors in patients with chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol 264:2481–2486CrossRefPubMedGoogle Scholar
Rakocevic Stojanovic V, Peric S et al (2016) Quality of life in patients with myotonic dystrophy type 2. J Neurol Sci 365:158–161CrossRefPubMedGoogle Scholar
Paul RH, Nash JM, Cohen R, Gilchist J, Goldstein J (2001) Quality of life and well-being of patients with myasthenia gravis. Muscle Nerve 24:512–516CrossRefPubMedGoogle Scholar
Rostedt A, Padua L, Stalberg E (2006) Validation of the Swedish version of the disease-specific myasthenia gravis questionnaire. Neurol Sci 27:91–96CrossRefPubMedGoogle Scholar
Raggi A, Leonardi M, Antozzi C, Confaloineri P, Maggi L, Cornelio F et al (2010) Concordance between severity of disease, disability, and health-related quality of life in myasthenia gravis. Neurol Sci 31:41–45CrossRefPubMedGoogle Scholar
Winter Y, Schepelmann K, Spottke AE, Claus D, Grothe C, Schroder R et al (2010) Health-related quality of life in ALS, myasthenia gravis, and facioscapulohumeral muscular dystrophy. J Neurol 257:1473–1481CrossRefPubMedGoogle Scholar
Rostedt A, Padua L, Stalberg EV (2006) Correlation between regional myasthenic weakness and mental aspects of quality of life. Eur J Neurol 13:191–193CrossRefPubMedGoogle Scholar